Aims Psychotropic medication may be associated with adverse effects, particularly in people with diabetes. We conducted a systematic review of observational studies investigating the association between antidepressant or antipsychotic drug prescribing and diabetes outcomes. Methods We systematically searched PubMed, EMBASE, and PsycINFO to 15th August 2022 to identify eligible studies. We used the Newcastle-Ottawa scale to assess study quality and performed a narrative synthesis. Results We included 18 studies, 14 reporting on antidepressants and four on antipsychotics. There were 11 cohort studies, one self-controlled before and after study, two case-control studies, and four cross-sectional studies, of variable quality and highly heterogeneous in terms of study population, exposure definition and outcome analysed. Antidepressant prescribing may be associated with increased risk of macrovascular outcomes, whilst evidence on antidepressant and antipsychotic prescribing and glycaemic control was mixed. Few studies reported on microvascular complications and cardiometabolic factors other than glycaemic control and just one study reported on antipsychotics and diabetes complications. Conclusions There has been little study of antidepressant and antipsychotic drug prescribing in relation to diabetes outcomes. Further, more methodologically robust, research is needed to inform and enhance antidepressant and antipsychotic drug prescribing and monitoring practices in people with diabetes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.